For example, a phase III trial demonstrated that the combination of erlotinib, a first-generation EGFR-TKI, and gemcitabine improved the survival of patients with advanced pancreatic cancer; however, this improvement was limited [15]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.